

INSTRUCTIONS FOR USE



EN

Anti-CMV IgM

REF 9Z9501M
SM9Z9501M

IVD

Rx Only



INTENDED USE

The Anti-CMV IgM is an ELISA-based test system designed for the qualitative detection of IgM class antibodies to cytomegalovirus (CMV) in human serum. The Test System is intended to be used to evaluate serologic evidence of primary or reactivated infection with CMV. This product is not FDA cleared (approved) for use in testing (i.e., screening) blood or plasma donors. This test is intended for *In Vitro* diagnostic use only.

SIGNIFICANCE AND BACKGROUND

Cytomegalovirus (CMV) infections are widespread and usually asymptomatic; however, the virus may persist as a latent or chronic infection (1). The relatively frequent incidence and often-severe disease in newborns and immunosuppressed individuals clearly establishes this agent as an important human pathogen (2 - 4). Scientists classify CMV infections as follows:

Congenital	-	Acquired before birth
Perinatal	-	Acquired at birth
Postnatal	-	Acquired after birth

Health professionals must be guarded with the prognosis for congenitally infected infants who are asymptomatic at birth. Ten to 25% of infants may subsequently develop hearing loss (7). Five to 10% of infants may exhibit various degrees of mental retardation and central nervous system motor disorders (5). Surveys show the incidence of congenital CMV infection to be from 0.5 - 2.5%. Consequently, a careful documentation of the long-term effects of intrauterine infection is important (8).

Perinatally infected infants start excreting CMV three to 12 weeks after delivery, and with rare exception, remain asymptomatic (9). Acquisition of postnatal CMV infections can occur through close contact with individuals who are shedding the virus (2). CMV has been isolated from saliva, urine, breast milk, cervical secretions, and semen. Consequently, the transmission of the virus may occur through a variety of mechanisms (6 - 8). Sexual transmission of the virus appears to contribute to the acquisition of the virus by young adults (10). Although the acquisition age for CMV infection varies with socioeconomic conditions, only about 10 - 15% of children in the United States are seropositive. By age 35 however, about 50% of the population is seropositive (2 - 4).

The majority of individuals contracting postnatal CMV infections remain asymptomatic (2 - 4). A small percentage of individuals will develop a negative heterophile-antibody infectious mononucleosis syndrome. Characteristics of CMV mononucleosis include fever, lethargy, and atypical lymphocytosis; whereas, in Epstein-Barr virus induced infectious mononucleosis, pharyngitis, lymphadenopathy, and splenomegaly are the chief clinical features (11 - 12).

In immunocompromised patients, CMV infections happen frequently, often from reactivation of latent infection, and may be life-threatening (2 - 4). These patients include allograft recipients, cancer patients, and patients with acquired immunodeficiency syndrome (AIDS) (4, 13, and 15). Clinical manifestations of CMV disease in immunocompromised patients range from CMV mononucleosis to pneumonia, hepatitis, pericarditis, and encephalitis (4).

CMV infections may occur following blood transfusions, and the risk of infection increases with the number of donors and the volume of blood given (4). Seronegative recipients may contract primary infection via blood from a seropositive donor. In seropositive recipients, reactivated latent infection may occur. Most transfusion acquired CMV infections are either subclinical or characterized by CMV mononucleosis (2 - 4). However, in specific groups of patients, considerable morbidity and mortality can result from a transfusion-acquired primary CMV infection. These patients are immunocompromised and include premature infants, pregnant women, cancer patients, and transplant recipients (4 - 14). In these patients, transfusion acquired CMV infections can be prevented by giving only blood from seronegative donors to seronegative recipients (4 - 14).

Serologic procedures, which measure IgG antibodies to CMV, can aid in the diagnosis of CMV infection when testing paired acute and convalescent sera simultaneously and seroconversion, or a significant rise in titer, can be demonstrated (15). In addition, serologic procedures may aid in the prevention of transfusion acquired CMV infections by assessing the serologic status of donors and recipients (4 - 14).

Production of the IgM class of antibodies begins during the first 2 to 3 weeks of infection with CMV and exists only transiently in most patients (16, 17). Serologic procedures that measure the presence of IgM antibodies help discriminate between primary and recurrent infections. Recurrent infections rarely create IgM antibodies (16).

High affinity IgG antibodies to CMV, if present in a sample, may interfere with the detection of IgM specific antibody (18, 23). High affinity IgG antibody may preferentially bind to CMV antigen leading to false negative IgM results (18). Also, rheumatoid factor, if present along with antigen specific IgG, may bind to the IgG causing false positive IgM results (19). Remove IgG from the sample before testing for IgM to eliminate both of the above problems (20 - 23). Scientists have used several different methods of separating IgG. These include gel filtration (20), absorption with protein A (21), ion exchange chromatography (22), and precipitation of IgG with anti-human IgG serum (23).

PRINCIPLE OF THE ASSAY

The Anti-CMV IgM is designed to detect IgM class antibodies to CMV in human sera. Creation of the sensitized wells of the plastic microwell strips occurred using passive adsorption with CMV IgM antigen. The test procedure involves three incubation steps:

1. Test sera are diluted with the Sample Diluent provided. The Sample Diluent contains anti-human IgG that precipitates and removes IgG and rheumatoid factor from the sample leaving IgM free to react with the immobilized antigen. During sample incubation any antigen specific IgM antibody in the sample will bind to the immobilized antigen. The plate is washed to remove unbound antibody and other serum components.
2. Peroxidase Conjugated goat anti-human IgM is added to the wells and the plate is incubated. The Conjugate will react with IgM antibody immobilized on the solid phase in step 1. The wells are washed to remove unbound Conjugate.
3. The microwells containing immobilized peroxidase Conjugate are incubated with peroxidase Substrate Solution. Hydrolysis of the Substrate by peroxidase produces a color change. After a period of time, the reaction is stopped and the color intensity of the solution is measured photometrically. The color intensity of the solution depends upon the antibody concentration in the original test sample.

TEST SYSTEM COMPONENTS

Materials Provided:

Each Test System contains the following components in sufficient quantities to perform the number of tests indicated on the packaging label. **NOTE:** The following components contain Sodium Azide as a preservative at a concentration of <0.1% (w/v): Controls, Calibrator and Sample Diluent.

Kit Component	Quantity 	Description
PLATE	1	Plate: 96 wells configured in twelve, 1x8-well, strips coated with CMV antigen (strain AD-169) harvested from MRC-5 cells. The strips are packaged in a strip holder and sealed in an envelope with desiccant.
CONJ	1	Conjugate: Conjugated (horseradish peroxidase) goat anti-human IgM (κ chain specific). One, 15mL, white-capped bottle. Ready to use.
CTRL +	1	Positive Control (Human Serum): 0.35mL, red-capped vial. 21X concentrate.
CAL	1	Calibrator (Human Serum): 0.5mL, blue-capped vial. 21X concentrate.
CTRL -	1	Negative Control (Human Serum): 0.35mL, green-capped vial. 21X concentrate.
DIL SPE	1	Sample Diluent: 30mL, green-capped, bottle containing Tween-20, bovine serum albumin and phosphate-buffered-saline. Purple solution. Ready to use.
SOLN TMB	1	TMB: 15mL, amber-capped, amber bottle containing 3, 3', 5, 5' - tetramethylbenzidine (TMB). Ready to use.
SOLN STOP	1	Stop Solution: 15mL, red-capped bottle containing 1M H ₂ SO ₄ , 0.7M HCl. Ready to use.



<div style="border: 1px solid black; display: inline-block; padding: 2px 5px; margin-right: 5px;">WASH</div> <div style="border: 1px solid black; display: inline-block; padding: 2px 5px;">10X</div>	1	Wash Buffer Concentrate (10X): Dilute 1 part concentrate + 9 parts deionized or distilled water. 100mL, clear-capped bottle containing a 10X concentrated phosphate-buffered-saline and Tween-20 solution (blue solution). NOTE: 1X solution will have a pH of 7.2 ± 0.2.
---	---	--

NOTE: The following components are not Test System Lot Number dependent and may be used interchangeably with the ZEUS ELISA Test Systems: TMB, Stop Solution, and Wash Buffer.

MATERIALS REQUIRED BUT NOT PROVIDED

1. ELISA microwell reader capable of reading at a wavelength of 450nm. **NOTE: Use of a single (450nm), or dual (450/620 - 650nm), wavelength reader is acceptable. Dual wavelength is preferred, as the additional reference filter has been determined to reduce potential interference from anomalies that may absorb light.**
2. Pipettes capable of accurately delivering 10 - 200µL.
3. Multichannel pipette capable of accurately delivering 50 - 200µL.
4. Reagent reservoirs for multichannel pipettes.
5. Wash bottle or microwell washing system.
6. Distilled or deionized water.
7. One-liter graduated cylinder.
8. Serological pipettes.
9. Disposable pipette tips.
10. Paper towels.
11. Laboratory timer to monitor incubation steps.
12. Disposal basin and disinfectant (i.e., 10% household bleach - 0.5% sodium hypochlorite).

STORAGE CONDITIONS

	Coated Microwell Strips: Immediately reseal extra strips with desiccant and return to proper storage. After opening, strips are stable for 60 days, as long as the indicator strips on the desiccant pouch remain blue.
	Conjugate – DO NOT FREEZE.
	Unopened Kit, Calibrator, Positive Control, Negative Control, TMB, Sample Diluent.
	Stop Solution: 2 - 25 °C Wash Buffer (1X): 20 - 25°C for up to 7 days, 2 - 8°C for 30 days Wash Buffer (10X): 2 - 25°C

PRECAUTIONS

1. For *In Vitro* diagnostic use.
2. Follow normal precautions exercised in handling laboratory reagents. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the ELISA plate do not contain viable organisms. However, consider the strips **potentially biohazardous materials** and handle accordingly.
4. The Controls are **potentially biohazardous materials**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, handle these products at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories": Current Edition; and OSHA's Standard for Bloodborne Pathogens (36).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20 - 25°C) before starting the assay.** Return unused reagents to refrigerated temperature immediately after use.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual wash solution; (e.g., by blotting or aspiration) before adding Conjugate or Substrate. Do not allow the wells to dry out between incubations.

7. The Sample Diluent, Controls, and Calibrator contain Sodium Azide at a concentration of <0.1% (w/v). Sodium Azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions upon hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing Sodium Azide.
8. The Stop Solution is TOXIC if inhaled, has contact with skin or if swallowed. It can cause burns. In case of accident or ill feelings, seek medical advice immediately.
9. The TMB Solution is HARMFUL. It is irritating to eyes, respiratory system and skin.
10. The Wash Buffer concentrate is an IRRITANT. It is irritating to eyes, respiratory system and skin.
11. Wipe the bottom of the plate free of residual liquid and/or fingerprints that can alter optical density (OD) readings.
12. Dilution or adulteration of these reagents may generate erroneous results.
13. Do not use reagents from other sources or manufacturers.
14. TMB Solution should be colorless, very pale yellow, very pale green, or very pale blue when used. Contamination of the TMB with Conjugate or other oxidants will cause the solution to change color prematurely. Do not use the TMB if it is noticeably blue in color.
15. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
16. Avoid microbial contamination of reagents. Incorrect results may occur.
17. Cross contamination of reagents and/or samples could cause erroneous results.
18. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
19. Avoid splashing or generation of aerosols.
20. Do not expose reagents to strong light during storage or incubation.
21. Allowing the microwell strips and holder to equilibrate to room temperature prior to opening the protective envelope will protect the wells from condensation.
22. Collect the wash solution in a disposal basin. Treat the waste solution with disinfectant (i.e.: 10% household bleach - 0.5% Sodium Hypochlorite). Avoid exposure of reagents to bleach fumes.
23. Caution: Neutralize any liquid waste at an acidic pH before adding to a bleach solution.
24. Do not use ELISA plate if the indicator strip on the desiccant pouch has turned from blue to pink.
25. Do not allow the Conjugate to come in contact with containers or instruments that may have previously contained a solution utilizing Sodium Azide as a preservative. Residual amounts of Sodium Azide may destroy the Conjugate's enzymatic activity.
26. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (sodium hypochlorite) may destroy the biological activity of many of the reactive reagents within this Test System.

SPECIMEN COLLECTION

1. ZEUS Scientific recommends that the user carry out specimen collection in accordance with CLSI document M29: [Protection of Laboratory Workers from Infectious Disease \(Current Edition\)](#).
2. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, consider all blood derivatives potentially infectious.
3. Use only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures in this assay (31, 32). Do not use if there are any added anticoagulants or preservatives. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
4. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2 - 8°C, for no longer than 48 hours. If a delay in testing is anticipated, store test sera at -20°C or lower. Avoid multiple freeze/thaw cycles which may cause loss of antibody activity and give erroneous results. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine stability criteria for its laboratory (24).

ASSAY PROCEDURE

1. Remove the individual components from storage and allow them to warm to room temperature (20 - 25°C).
2. Determine the number of microwells needed. Allow for six Control/Calibrator determinations (one Reagent Blank, one Negative Control, three Calibrators and one Positive Control) per run. Run a Reagent Blank on each assay. Check software and reader requirements for the correct Controls/Calibrator configurations. Return unused strips to the resealable pouch with desiccant, seal, and return to storage between 2 - 8°C.

EXAMPLE PLATE SET-UP		
	1	2
A	Blank	Patient 3
B	Negative Control	Patient 4
C	Calibrator	Etc.
D	Calibrator	
E	Calibrator	
F	Positive Control	
G	Patient 1	
H	Patient 2	

3. Prepare a 1:21 dilution (e.g.: 10µL of serum + 200µL of Sample Diluent) of the Negative Control, Calibrator, Positive Control, and each patient serum.
4. To individual wells, add 100µL of each diluted Control, Calibrator and patient specimen. Ensure that the samples are properly mixed. Use a different pipette tip for each sample.
5. Add 100µL of Sample Diluent to well A1 as a Reagent Blank. Check software and reader requirements for the correct Reagent Blank well configuration.
6. Incubate the plate at room temperature (20 – 25°C) for 25 ± 5 minutes.
7. Wash the microwell strips 5 times.
 - a. **Manual Wash Procedure:**
 1. Vigorously shake out the liquid from the wells.
 2. Fill each microwell with Wash Buffer. Make sure no air bubbles are trapped in the wells.
 3. Repeat steps 1. and 2. for a total of 5 washes.
 4. Shake out the wash solution from all the wells. Invert the plate over a paper towel and tap firmly to remove any residual wash solution from the wells. Visually inspect the plate to ensure that no residual wash solution remains. Collect wash solution in a disposable basin and treat with disinfectant at the end of the day's run.
 - b. **Automated Wash Procedure:**
If using an automated microwell wash system, set the dispensing volume to 300 – 350µL/well. Set the wash cycle for 5 washes with no delay between washes. If necessary, the microwell plate may be removed from the washer, inverted over a paper towel and tapped firmly to remove any residual wash solution from the microwells.
8. Add 100µL of the Conjugate to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
9. Incubate the plate at room temperature (20 – 25°C) for 25 ± 5 minutes.
10. Wash the microwells by following the procedure as described in step 7.
11. Add 100µL of TMB to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
12. Incubate the plate at room temperature (20 – 25°C) for 10 – 15 minutes.
13. Stop the reaction by adding 50µL of Stop Solution to each well, including the Reagent Blank well, at the same rate and in the same order as the TMB. Positive samples will turn from blue to yellow. After adding the Stop Solution, tap the plate several times to ensure that the samples are thoroughly mixed.
14. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the Reagent Blank. Read the plate within 30 minutes of the addition of the Stop Solution.

ABBREVIATED TEST PROCEDURE

1. Dilute Serum 1:21.
2. Add diluted sample to microwell – 100µL/well.
3. —————→ *Incubate 25 ± 5 minutes.*
4. Wash.
5. Add Conjugate – 100µL/well.
6. —————→ *Incubate 25 ± 5 minutes.*
7. Wash.
8. Add TMB – 100µL/well.
9. —————→ *Incubate 10 – 15 minutes.*
10. Add Stop Solution – 50µL/well – Mix.
11. READ within 30 minutes.

QUALITY CONTROL

1. Each time the assay is performed, the Calibrator must be run in triplicate. A Reagent Blank, Negative Control, and Positive Control must also be included.
2. Calculate the mean of the three Calibrator wells. If any of the three values differ by more than 15% from the mean, discard that value and calculate the mean using the remaining two wells.
3. The mean OD value for the Calibrator, Positive Control, and Negative Control should fall within the following ranges:

	<u>OD Range</u>
Negative Control	≤ 0.250
Calibrator	≥ 0.300
Positive Control	≥ 0.500

- a. The OD of the Negative Control divided by the mean OD of the Calibrator should be ≤ 0.9 .
 - b. The OD of the Positive Control divided by the mean OD of the Calibrator should be ≥ 1.25 .
 - c. If the above conditions are not met the test should be considered invalid and should be repeated.
4. The Positive Control and Negative Control are intended to monitor for substantial reagent failure, but will not ensure precision at the assay Cutoff.
 5. Additional Controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.
 6. Refer to CLSI document C24: Statistical Quality Control for Quantitative Measurement Procedures for guidance on appropriate QC practices.

INTERPRETATION OF RESULTS

1. Calculations:

- a. **Correction Factor:** The manufacturer determined a Cutoff OD Value for positive samples and correlated it to the Calibrator. The Correction Factor (CF) allows for the determination of the Cutoff Value for positive samples. It will also correct for slight day-to-day variations in test results. The Correction Factor is determined for each lot of components and is printed on the Component Label located in the Test System box.
- b. **Cutoff OD Value:** To obtain the Cutoff OD Value, multiply the CF by the mean OD of the Calibrator determined above.
($CF \times \text{Mean OD of Calibrator} = \text{Cutoff OD Value}$)
- c. **Index Values/OD Ratios:** Calculate the Index Value/OD Ratio for each specimen by dividing its OD Value by the Cutoff OD from step b.

Example: Mean OD of Calibrator	=	0.793
Correction Factor (CF)	=	0.25
Cutoff OD	=	$0.793 \times 0.25 = 0.198$
Unknown Specimen OD	=	0.432
Specimen Index Value/OD Ratio	=	$0.432 / 0.198 = 2.18$

2. **Interpretations:** Index Values/OD Ratios are interpreted as follows.

	<u>Index Value/OD Ratio</u>
Negative Specimens	≤ 0.90
Equivocal Specimens	0.91 – 1.09
Positive Specimens	≥ 1.10

- a. An OD ratio ≤ 0.90 indicates no significant amount of IgM antibodies to CMV detected. A negative result indicates no current or reactivated infection with CMV. However, specimens taken too early during a primary infection may not have detectable levels of IgM antibody. When health care professionals suspect a primary infection, take another specimen within seven days, and test concurrently in the same assay, with the original specimen, to look for seroconversion.
- b. An OD ratio ≥ 1.10 indicates that IgM antibodies specific to CMV were detected. A positive value indicates a primary or reactivated infection with CMV. Presume that such individuals are at risk of transmitting CMV infection but are not necessarily currently contagious.
- c. Specimens with OD ratio values in the equivocal range (0.91 – 1.09) should be retested in duplicate. Report any two of the three results which agree. Evaluate repeatedly equivocal specimen by using an alternate serologic procedure and/or re-evaluate by drawing another sample one to three weeks later.

LIMITATIONS OF THE ASSAY

1. A negative result does not rule out a primary or reactivated infection with CMV.
2. Since CMV specific IgM antibody usually does not develop until the patient has been clinically ill for a week or more, samples taken too early in the course of a primary infection may not have detectable levels of IgM (33).
3. In immunocompromised patients the ability to produce an IgM response may be impaired and CMV specific IgM may be falsely negative during an active infection (15, 34).
4. CMV specific IgM antibodies may reappear during reactivation of CMV infection (15, 17, and 33).
5. Results of the Anti-CMV IgM are not by themselves diagnostic. Interpret results in light of the patient's clinical condition and the results of other diagnostic procedures.
6. Patients may continue to produce CMV specific IgM antibody for six to nine months following a primary infection (15, 27, and 33).
7. Isolation of CMV from urine or the presence of CMV IgM antibody during the first week of life usually provides a reliable diagnosis of congenital CMV infection (35). Do not use specimens collected for viral isolation or for detection of CMV IgM beyond the first week after birth to distinguish congenital infection from infection acquired at, or shortly after, birth (35).
8. CMV specific IgG antibodies may compete with IgM for binding sites and cause false negative results. Rheumatoid factor, if present along with CMV specific IgG, will cause false positive results. The absorbent incubation step will remove greater than 99% of IgG from the test specimens, and significantly reduce the incidence of false results.
9. Heterotypic IgM antibody responses may occur in patients infected with Epstein-Barr virus and give false positive results in the CMV-IgM ELISA.

EXPECTED RESULTS

The incidence of CMV infection varies with age, geographic location, sexual behavior, and socioeconomic status (33). However, CMV is the most common cause of congenital viral infection (16, 33). In the United States, infection at birth affects approximately 1% of infants (16, 33). CMV specific IgM usually develops after a patient has been clinically ill for at least a week or more (33). Most (83%) of patients produce IgM transiently within 16 weeks of seroconversion (16). However, some patients may continue to produce IgM for six to nine months after seroconversion (15 - 17).

PERFORMANCE CHARACTERISTICS

1. Comparative Study

A study was conducted to compare the Anti-CMV IgM to another commercially available ELISA test system for detection of IgM antibodies to CMV. A total of 101 serum samples, obtained from a reference laboratory, were assayed by the two methods. Below is a summary of these results:

		Reference ELISA		
		Positive	Negative	Equivocal*
Anti-CMV IgM	Positive	25	1	2
	Negative	2	66	2
	Equivocal*	3	0	0
Specificity = 98.5% (66/67)		Sensitivity = 92.5% (25/27) (91/94)		Concordance = 96.8%
*Equivocal results were not included in the calculations for sensitivity, specificity, and concordance				

Test results of the two procedures, for three specimens, did not agree. A third commercial ELISA procedure for the detection of IgM antibodies retested the specimens and was in agreement with the ZEUS ELISA Test System.

2. Reproducibility

Technicians tested six specimens to determine intra-assay and inter-assay variation; two strong positive specimens, two specimens near the cut off zone, and two low negative specimens. On each of three days, a technician tested each specimen once a day, eight times each, resulting in 24 test points. A responsible party then calculated the mean OD ratio and coefficient of variation from the resulting data. Depiction of the results of the experiment is below.

	Intra-Assay (n=8)						Inter-Assay (n=3)	
	Run 1		Run 2		Run 3		Mean Ratio	% CV
	Mean Ratio	% CV	Mean Ratio	% CV	Mean Ratio	% CV		
Serum 1	6.48	3.7	7.68	3.1	5.82	4.7	6.66	11.6
Serum 2	7.27	4.3	8.92	1.7	6.88	4.4	7.69	11.5
Serum 3	2.73	6.0	3.19	7.7	2.69	4.0	2.87	7.9
Serum 4	1.30	3.2	1.54	7.3	1.20	5.7	1.35	10.8
Serum 5	0.55	7.2	0.66	12.2	0.55	8.3	0.59	9.1
Serum 6	0.67	7.1	0.77	5.6	0.56	5.6	0.67	13.1

3. Cross Reactivity

Studies assessed the possible interference with the test procedure by sera containing rheumatoid factor or antinuclear antibodies. Ten rheumatoid factor positive sera specimens with latex agglutination titers from 1:80 to 1:640 by the Anti-CMV IgM procedure. After pretreatment with absorbent, all ten sera were negative in the Anti-CMV IgM procedure. Ten ANA positive sera with IFA titers of 1:80 to 1:1280 were tested by the Anti-CMV IgM procedure and nine of ten were negative. One serum with an ANA titer of 1:1280 was weakly positive but was also positive in another CMV IgM ELISA procedure. These studies indicate that interference with the test procedure by rheumatoid factor and antinuclear antibodies is minimal. Sera with IgM IFA titers to Herpes Simplex virus (1:8 - 1:640), and Varicella-Zoster virus (1:10 - 1:80) were tested for cross reactivity with the ELISA CMV IgM Test System. None of five HSV IgM positive sera, and only one of nine VZ IgM positive sera were positive in the ELISA CMV IgM Test System.

REFERENCES

1. Jordon MC: Latent infection and the elusive cytomegalovirus. *Rev. Infect. Dis.* 5:205-215, 1983.
2. Starr SE: Cytomegalovirus. *Ped. Clin. N. Am.* 26:282-293, 1979.
3. Weller TH: Clinical spectrum of cytomegalovirus infection. In: Nahmias AJ, Dowdle WR, and Schinazi RF, eds. *The Human Herpes Viruses, an interdisciplinary perspective.* Elsevier/North Holland Publishing Co., New York, pp. 20-30, 1980.
4. Adler SP: Transfusion-associated cytomegalovirus infections. *Rev. Infect. Dis.* 5:977-993, 1983.
5. Melish ME and Hanshaw JB: Congenital cytomegalovirus infection: Development progress of infants detected by routine screening. *Am. J. Dis. Child.* 126:190-194, 1973.
6. Reynolds DW, Stagno S, and Alford CA: Laboratory diagnosis of cytomegalovirus infections. In: Lennette EH and Schmidt NJ, eds. *Diagnostic Procedures for Viral, rickettsial, and Chlamydial Infections*, 5th ed., American Public Health Association, Washington, DC, 1979.
7. Nankervis G: Long term follow-up of cytomegalic inclusion disease of infancy, *Pediatrics* 46:403-410, 1970.
8. Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, and Alford CA: Congenital cytomegalovirus infections: Occurrence in an immune population. *N. Engl. J. Med.* 296:1254-1258, 1978.
9. Stern H: Isolation of cytomegalovirus and clinical manifestations of infection at different ages. *Br. Med. J.* 1:665-669, 1968.
10. Handsfield HH, Chandler SH, Caine VA, Meyers JD, Corey L, Medeiros E, and McDougall JK: Cytomegalovirus infection in sex partners: Evidence for sexual transmission. *J. Infect. Dis.* 151:344-348, 1985.
11. Jordon MC, Rousseau WE, Noble GR, Stewart JA, Noble CR, and Chin TDY: Spontaneous cytomegalovirus mononucleosis. *Ann. Intern. Med.* 79:153-160, 1973.
12. Umetsu M, Chiba Y, Horino K, Chiba S, and Kakao T: Cytomegalovirus-monomucleosis in a newborn infant. *Arch. Dis. Child.* 50:396-398, 1975.
13. Simmons RL, Matas AJ, Rattazzi LC, Balfour HH, Howard RJ, and Najarian JS: Clinical characterization of the lethal cytomegalovirus infection following renal transplantation surgery. *Surgery* 82:537-546, 1977.
14. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, and Prober CG: Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. *J. Pediatrics* 98:281-287, 1981.
15. Drew WL: Diagnosis of cytomegalovirus infection. *Rev. Infect. Dis.* 10:5468-5475, 1988.
16. Stagno S, Tinker MK, Elrod C, Fuccillo DA, Cloud G, and O'Beirne AJ: Immuno-globulin M antibodies detected by enzyme-linked immunosorbent assay and radioimmuno-assay in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants. *J. Clin. Micro.* 21:930-935, 1985.
17. Charnesky MA, Ray CG, and Smith TF: Laboratory diagnosis of viral infections. *Cumitech 15*, American Society for Microbiology, Washington, DC, 1982.
18. Fraser KB, Shirodaria PV, and Stanford CF: Fluorescent staining and human IgM. *Br. Med. J.* 3:707, 1971.
19. Salonen E-M, Vaheri A, Suni J, and Wager O: Rheumatoid factor in acute viral infections: Interference with determination of IgM, IgG, and IgA antibodies in an enzyme immunoassay. *J. Infect. Dis.* 142:250-255, 1980.
20. Pyndiah N, Krech U, Price P, and Wilhelm J: Simplified chromatography separation of immunoglobulin M from G and its application to Toxoplasma indirect immunofluorescence. *J. Clin. Micro.* 9:170-174, 1979.
21. Sumaya CV, Ench Y, and Pope RM: Improved test for IgM antibody to Epstein-Barr virus using an absorption step with *Staphylococcus aureus*. *J. Infect. Dis.* 146:518-523, 1982.
22. Johnson RB and Libby R: Separation of immunoglobulin M (IgM) essentially free of IgG from serum for use in systems requiring assay of IgM-type antibodies without interference from rheumatoid factor. *J. Clin. Micro.* 12:451-454, 1980.
23. Joassin L and Reginsster M: Elimination of nonspecific cytomegalovirus immunoglobulin M activities in the enzyme-linked immunosorbent assay by using anti-human immunoglobulin G. *J. Clin. Micro.* 23:576-581, 1984.
24. Engvall E and Perlman P: Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. *Immunochem.* 8:871-874, 1971.
25. Engvall E and Perlman P: Enzyme-linked immunosorbent assay (ELISA) III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen coated tubes. *J. Immunol.* 109:129-135, 1972.
26. Booth JC, Hannington G, Bakin TMF, Stern H, Kangro H, Griffiths PD, and Heath RB: Comparison of enzyme-linked immunosorbent assay, radioimmunoassay, complement fixation, anticomplement immunofluorescence and passive hemagglutination techniques for detecting cytomegalovirus IgG antibody. *J. Clin. Pathol.* 35:1345-1348, 1982.
27. Dylewski JS, Rasmussen L, Mills J, and Merigan TC: Large scale serological screening for cytomegalovirus antibodies in homosexual males by enzyme-linked immunosorbent assay. *J. Clin. Micro.* 19:200-203, 1984.
28. Voller A, Bartlett A, and Bidwell DE: Enzyme immunoassays with special reference to ELISA techniques. *J. Clin. Pathol.* 31:507-520, 1978.
29. Phipps PH, Gregoire L, Rossier E, and Perry E: Comparison of five methods of cytomegalovirus antibody screening of blood donors. *J. Clin. Micro.* 18:1296-1300, 1983.

30. Adler SP, McVoy M, Biro VG, Britt WJ, Hider P, and Marshall D: Detection of cytomegalovirus antibody with latex agglutination. *J. Clin. Micro.* 22:68-70, 1985.
31. Procedures for the collection of diagnostic blood specimens by venipuncture: Second Edition: Approved Standard (1984). Published by National Committee for Clinical Laboratory Standards.
32. Procedures for the Handling and Processing of Blood Specimens. NCCLS Document H18-A, Vol. 10, No. 12, Approved Guideline, 1990.
33. Drew WJ: Herpesviridae: Cytomegalovirus. In: A Balows, WJ Hausler, and EH Lennette, eds. *Laboratory Diagnosis of Infectious Diseases*, Vol II. Springer-Verlag, New York, pp. 247-260, 1988.
34. Rasmussen L, Kelsall D, Nelson R, Carney W, Hirsch M, Winston D, Preiksaitis and Merigan TC: Virus-specific IgG and IgM antibodies in normal and immuno-compromised subjects infected with cytomegalovirus. *J. Infect. Dis.* 145:191-199, 1982.
35. Stagno S, Pass RF, Reynolds DW, Moore MA, Nahmias AJ, and Alford CA: Comparative study of diagnostic procedures for congenital cytomegalovirus infection. *Pediatrics* 65:251-257, 1980.
36. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational Exposure to Bloodborne Pathogens, Final Rule. *Fed. Register* 56:64175-64182, 1991.

GLOSSARY OF SYMBOLS

The following symbols **may** have been used in the labelling of this product or products associated with this product.

Symbol	Description	Symbol	Description
	Manufacturer		Keep away from sunlight
IVD	<i>In vitro</i> diagnostic medical device	PLATE	Plate
REF	Catalogue number	CONJ	Conjugate
	Sufficient for <i>n</i> tests	CTRL +	Positive Control
LOT	Batch code	CTRL -	Negative Control
	Use by	CAL	Calibrator
	Temperature limitation	DIL SPE	Sample Diluent
CONT	Contents	SOLN TMB	TMB
UDI	Unique Device Identifier	SOLN STOP	Stop Solution
	Consult the warnings and precautions	WASH 10X	Wash Buffer Concentrate (10X)
	Consult electronic instructions for use	EN	English
	Store in the upright position	Made in the USA	Made in the USA
RX Only	Applicable for U.S.A: Prescription <i>in vitro</i> diagnostic product		Corrosive
	Hazardous Communication		


ZEUS Scientific
 200 Evans Way, Branchburg, New Jersey, 08876, USA
 Toll Free (U.S.): 1-800-286-2111, Option 2
 International: +1 908-526-3744
 Fax: +1 908-526-2058
 Website: www.zeusscientific.com

For US Customer Service contact your local distributor.
 For US Technical Support contact ZEUS Scientific, call toll free or e-mail support@zeusscientific.com.
 For Customer Service and Technical Support inquiries outside the US, please contact your local Sebia subsidiary or authorized distributor.

©2025 ZEUS Scientific All Rights Reserved.